...was for me, since I trade non-directional strategies. Such up day must be good for Trajan for getting in, since this what he trades is mostly directional, right Trajan ? Trdmac, I`m originally born in Europe, living in US all my adult life around NYC, now temporarily back in Europe again, but I have to say that NC is one of my favorite places to live, however is pretty far for me now to attend seminar. I believe that some of them are not that ugly as we think, but the point is that most of them really are. I`ve tried many trading strategies, and still trade systems but whatever I have valuable is made by myself. I`m sure there is number of seminars worth something, but the truth is that their principal business is not to teach anybody how to profit from trading, but how to blind newbies, with all respect to those who don`t do that, but they are exceptions who confirm the rule anyway.
While non-directional for BPUR seems to not having great view I added vertical spread short p 5 long p 2.5. Combined with existing position looks quite interesting, but somewhat complicated.
We use volume and volatility in our alerts so I thought you would want to check that out. We also do some filtering for only optionable stocks etc.
This came out today, looks like the date is more like sometime this summer: CAMBRIDGE, Mass., May 30 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today notified Biopure Corporation (Nasdaq: BPUR - News) that it will complete its review and act on the company's biologic license application (BLA) for Hemopure® (hemoglobin glutamer - 250 bovine) by August 29, 2003. Biopure has applied to market Hemopure in the United States for the treatment of acutely anemic patients undergoing orthopedic surgery and for the elimination or reduction of red blood cell (RBC) transfusions. ADVERTISEMENT Biopure submitted its BLA on July 31, 2002. Under FDA performance goals in the Prescription Drug User Fee Act (PDUFA III), the agency has up to 10 months from the submission date to review and act on the BLA, making the original action due date June 1, 2003. As part of the normal review process, Biopure has responded to FDA questions regarding the application. The agency has classified the latest responses submitted in mid-May 2003 as additional analyses of previously submitted data, which under FDA standard operating procedures automatically provides the agency up to three months beyond the original action due date to review the data. This type of action is not unusual-the last 11 standard BLAs accepted for review by the FDA have undergone a 13-month review. "We're very pleased with the FDA's progress in reviewing our application," said Biopure President and CEO Thomas A. Moore. "We continue to work closely with the agency toward a final decision that will allow us to make Hemopure available as an alternative to red blood cell transfusion. We're also continuing our preparations to roll out the product to leading orthopedic surgery centers following approval." The BLA includes clinical data from a multinational, RBC-controlled Phase III orthopedic surgery trial and from a similar non-U.S. Phase III general non-cardiac surgery trial. It also contains an integrated database of all 22 Hemopure clinical trials, encompassing more than 1400 total subjects of which more than 800 received Hemopure. Hemopure is an oxygen therapeutic, or drug, consisting of chemically stabilized bovine hemoglobin formulated in a balanced salt solution. This stabilized hemoglobin circulates directly in plasma (the fluid part of blood) when infused, increasing oxygen diffusion to the body's tissues. The product is compatible with all blood types, can be stored for three years without refrigeration or special handling, and is purified through patented and proprietary techniques that are validated to remove potential contaminants, including infectious agents such as bacteria, viruses and transmissible spongiform encephalopathy (TSE) agents. Anemia is a shortage of RBCs in the body that can create an oxygen deficit and lead to cell damage, organ dysfunction or, in severe cases, death. Acute anemia, usually caused by blood loss, is the primary indication for a RBC transfusion. In 1999, approximately 1.4 million RBC units were transfused in 500,000 high blood loss orthopedic surgical procedures.* These statistics are expected to increase as the population ages. Conference Call Biopure will discuss the regulatory status of Hemopure in a conference call and webcast on Friday, May 30, 2003, at 3:00 p.m. ET. The dial-in numbers for investors and analysts are 1-800-387-5428 (US/Canada) and 1-706-634-1328 (International). A live audio webcast of the conference call will be available from the investor section of Biopure's web site at www.biopure.com and will be archived for 30 days. The webcast can also be heard by individual investors at www.companyboardroom.com and by institutional investors who subscribe to StreetEvents at www.streetevents.com. An audio replay of the conference call will be available from approximately 5:30 p.m. ET, May 30, 2003, until midnight June 6, 2003. To access the replay, dial 1-800-642-1687 (US/Canada) or 1-706-645-9291 (International/Local) and reference conference ID number 1003445.
Hope no one here had the misfortune of being long vega on bpur. I've seen vol come back in really quickly in the past but this takes the cake.